IDNA: ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF
ETF Education Report: ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF (IDNA)
What this ETF is trying to do
The ISHARES GENOMICS IMMUNOLOGY AND HEALTHCARE ETF (ticker: IDNA) is an exchange-traded fund that focuses on the healthcare sector. Specifically, it targets companies involved in genomics, immunology, and general healthcare.
Top Holdings
The following are the largest companies held by this ETF (note that this is a partial list):
• Moderna Inc (11.20%)
• Twist Bioscience Corp (7.70%)
• Iovance Biotherapeutics Inc (4.98%)
• Genmab AS (3.98%)
• Revolution Medicines Inc (3.79%)
• Bayer AG (3.60%)
• Merck & Co Inc (3.32%)
• Takeda Pharmaceutical Co Ltd (3.30%)
• Regeneron Pharmaceuticals Inc (3.29%)
• Incyte Corp (3.27%)
What the numbers show
When looking at ETF performance, it is important to distinguish between price return (how much the share price changed) and total return (which includes the impact of distributions).
• Year-to-Date (YTD): The price return is approximately 56.05%, while the total return is approximately 56.71%.
• One-Year: The price return was approximately 66.54%, and the total return was approximately 68.24%.
• Three-Year: The price return was approximately 106.41%, and the total return was approximately 113.65%.
For context, the estimated price from roughly one year ago was $24.54. The current price is $40.87.
Income and distribution explanation
This ETF provides some cash income through distributions. The distribution yield is approximately 0.69%. Over the last 12 months, there were 2 payouts. The distribution frequency is described as irregular or less frequent. It is important to remember that a distribution yield shows the cash paid out relative to the price, but it is not the same as the total return.
NAV erosion explanation
"NAV erosion" refers to a decline in the Net Asset Value (the actual value of the assets held by the fund). Some investors worry about erosion because it can mean the fund is losing value over time. For IDNA, the erosion-risk score is 100, and the label indicates "No price erosion detected." There is no severe erosion-risk flag for this ETF.
Pros
• The ETF has shown strong positive price returns over the one-year and three-year periods.
• The total return figures are higher than the price return figures, meaning distributions added to the overall value.
• The erosion-risk measurement is rated as "good."
Cons
• The five-year total return was approximately -9.71%.
• The distribution yield is relatively low at 0.69%.
• Distributions are irregular rather than occurring on a steady monthly or quarterly schedule.
Beginner takeaway
IDNA focuses on specialized healthcare companies like Moderna and Twist Bioscience. While it has seen significant price growth recently, long-term data (five years) shows a negative total return. Investors should always look at both price returns and total returns to see the full picture of how an ETF has performed.
Top Holdings
Structured portfolio holdings supplied by the ETF data provider. These figures are not generated by the AI article.
| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | MODERNA INC | MRNA | 11.20% |
| 2 | TWIST BIOSCIENCE CORP | TWST | 7.70% |
| 3 | IOVANCE BIOTHERAPEUTICS INC | IOVA | 4.98% |
| 4 | GENMAB AS | n/a | 3.98% |
| 5 | REVOLUTION MEDICINES INC ORDINARY SHARES | RVMD | 3.79% |
| 6 | BAYER AG | n/a | 3.60% |
| 7 | MERCK & CO INC | MRK | 3.32% |
| 8 | TAKEDA PHARMACEUTICAL CO LTD | n/a | 3.30% |
| 9 | REGENERON PHARMACEUTICALS INC | REGN | 3.29% |
| 10 | INCYTE CORP | INCY | 3.27% |